The Role of EGFR Inhibitor Therapy as Post-Operative Treatment for Early Stage NSCLC: A Controversial Question (audio)
- Author
- cancerGRACE - H. Jack West, MD
- Published
- Wed 17 Mar 2010
- Episode Link
- https://traffic.libsyn.com/secure/cancergrace/GRACEcast-049_Lung-Audio_Weiss_EGFR_for_NSCLC.mp3
Dr. Jared Weiss, medical oncologist from the Univ. of Pennsylvania, covers limited data and current clinical trials addressing potential role of EGFR inhibitors, and particularly Tarceva (erlotinib), as post-surgical treatment for advanced NSCLC.
